Investors - Highlights and Events - Recordati
Investor Relations
Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.
Upcoming Events
No upcoming events found.
Date:
November 10, 2026
-
November 10, 2026
Board of Directors’ meeting to approve the 2026 first nine months’ results, as additional voluntary financial reporting.
Date:
November 11, 2026
-
November 11, 2026
At 2.00 pm (CET): conference call on the 2026 first nine months’ results.
Revenue
Revenue trend 2021 - 2025 (million Euro)
1,580 1,853 2,082 2,342 2,618 2021 2021 2022 2022 2023 2023 2024 2024 2025 2025
Revenue by business unit 2021 - 2025 (million Euro)
3.0K 3.0K 2.5K 2.5K 2.0K 2.0K 1.5K 1.5K 1.0K 1.0K 500.0 500.0 0.0 0.0 2021 2021 2022 2022 2023 2023 2024 2024 2025 2025
Total Revenue split by Therapeutica area - FY 2025
(SPC 58.7%, Rare Disease 41.3%)
SPC - Cardiovascular
SPC - Urology
SPC - Gastro & Intestinal
SPC - Cough and Cold
SPC - Other Pharmaceuticals
Chemicals
RD - Metabolic
RD - Endocrinology
RD - Hema-Oncology
15% 16% 9% 5% 12% 10% 15% 16%
Pharmaceutical revenue (excluding Chemicals) split by Geographic - FY 2025
US
Italy
Other International Sales
France
Germany
Spain
Other Western Europe
Other CEE
Russia, Ukraine & Other CSI
Turkey
Portugal
North Africa
20% 13% 13% 7% 7% 9% 7% 7% 7% 5% 3%
Key P&L Data
| (million Euro) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | ||||
|---|---|---|---|---|---|---|---|---|---|
| (million Euro) Revenue |
FY 2025 2,618.4 |
FY 2024 2,341.6 |
FY 2023 2,082.3 |
FY 2022 1,853.3 |
FY 2021 1,580.1 |
||||
| (million Euro) Gross Profit as % of revenue |
FY 2025 1,787.7 68.3 |
FY 2024 1,600.3 68.3 |
FY 2023 1,422.6 68.3 |
FY 2022 1,286.6 69.4 |
FY 2021 1,152.3 72.9 |
||||
| (million Euro) Adjusted Gross Profit (1) as % of revenue |
FY 2025 1,854.4 70.8 |
FY 2024 1,637.8 69.9 |
FY 2023 1,481.6 71.1 |
FY 2022 1,336.4 72.1 |
FY 2021 1,152.3 72.9 |
||||
| (million Euro) Operating Income (EBIT) as % of revenue |
FY 2025 670.8 25.6 |
FY 2024 638.9 27.3 |
FY 2023 558.0 26.8 |
FY 2022 437.3 23.6 |
FY 2021 490.2 31.0 |
||||
| (million Euro) Adjusted Operating Income (Adj. EBIT) (2) as % of revenue |
FY 2025 774.9 29.6 |
FY 2024 684.4 29.2 |
FY 2023 626.6 30.1 |
FY 2022 536.1 28.9 |
FY 2021 504.6 31.9 |
||||
| (million Euro) Net Income as % of revenue |
FY 2025 443.6 16.9 |
FY 2024 416.5 17.8 |
FY 2023 389.2 18.7 |
FY 2022 312.3 16.9 |
FY 2021 386.0 24.4 |
||||
| (million Euro) Adjusted Net Income (3) as % of revenue |
FY 2025 651.1 24.9 |
FY 2024 568.9 24.3 |
FY 2023 524.6 25.2 |
FY 2022 473.3 25.5 |
FY 2021 424.6 26.9 |
||||
| (million Euro) EBITDA (4) as % of revenue |
FY 2025 991.1 37.8 |
FY 2024 865.8 37.0 |
FY 2023 769.6 37.0 |
FY 2022 672.8 36.3 |
FY 2021 602.3 38.1 |
1) Adjusted gross profit: Gross profit adjusted by the impact of non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3
2) Adjusted Operating Income: Net income before income taxes, financial income and expenses and non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3.
3) Adjusted Net Income: Net income excluding the amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory pursuant to IFRS 3, and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.
4) EBITDA: Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3
Balance Sheet at December 2025 (million Euro)
| Current Assets | 100.00% | 100.00% |
| Liabilities | 100.00% | 100.00% |
Net Debt - FY 2023 - 2025 (million Euro)
Net Debt / EBITDA1 - FY 2023 - 2025 (million Euro)
3.00x 3.00x 2.00x 2.00x 1.00x 1.00x 0.00x 0.00x 1.96x 2.4x 2.1x 2023 2023 2024 2024 2025 2025
1) EBITDA: Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3
Free Cash Flow1 - FY 2023 - 2025 (million Euro)
600.00% 600.00% 300.00% 300.00% 0.00% 0.00% 456 524 559 2023 2023 2024 2024 2025 2025
1) Operating cash flow excluding financing items, milestones, dividends, purchases of treasury shares net of proceeds from exercise of stock options
Adjusted Net Income Per Share (Euro)
4.0 4.0 2.0 2.0 0.0 0.0 2.0 6.2 2.5 5 12.75 73.169 2021 2021 2022 2022 2023 2023 2024 2024 2025 2025
Dividend per share (Euro)
1.34 1.34 0.0 0.0 1.05 1.11 1.15 1.27 1.34 2021 2021 2022 2022 2023 2023 2024 2024 2025 2025
Note on Dividend per Share 2025: Proposed by the Board of Directors
Net Income per share (Euro)
3.0 3.0 2.0 2.0 1.0 1.0 0.0 0.0 1.874 1.519 1.893 2.019 2.159 2021 2021 2022 2022 2023 2023 2024 2024 2025 2025
Presentations & Reports
Latest and previous presentations and reports including company presentations and financial results, annual & interim reports and archived materials…
Press Releases
Overview of our key milestones as a company and latest news and announcements
Annual Report 2025
Discover the 2025 Annual Report site
Share Price
Recordati share info and chart - by Teleborsa
Last price € 51.9
% Change -0.67%
Accum. volume 185,074
Capitalization € 10,875 M.